Pharmacoeconomics 2007; 25 (5): 355-363


Pharmaceutical patents are anachronistic holdovers from an era in which Abstract modern economic understanding and tax tools were unavailable. Superior mechanisms lie somewhere between a first best pricing solution for the entire economy at one extreme and the current arrangements at the other. We discuss the economics of suggested alternatives and suggest… (More)


1 Figure or Table

Cite this paper

@inproceedings{Grinols2007Pharmacoeconomics22, title={Pharmacoeconomics 2007; 25 (5): 355-363}, author={Earl L. Grinols and James W. Henderson}, year={2007} }